RY 173.64 -0.3672% SHOP 148.58 -0.6486% TD 82.36 -0.9263% ENB 64.21 -0.2641% BN 83.24 -1.0579% TRI 230.54 0.013% CNQ 46.58 3.4881% CP 109.8 1.4131% CNR 148.11 0.8031% BMO 143.82 0.3489% BNS 73.94 0.5029% CSU 4345.0 -1.0785% CM 90.555 -0.1158% MFC 44.31 0.113% ATD 76.82 0.0521% NGT 60.2 -0.1327% TRP 69.31 1.0939% SU 56.975 0.9658% WCN 255.98 -0.7868% L 181.13 -0.1268%
Last update at 2025-01-17T21:00:00Z
IDEXX Stock Suffers Due to Macroeconomic Issues and FX Woes
Wed 15 Jan 25, 02:38 PMWhy Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term
Thu 26 Dec 24, 02:45 PMIDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Mon 23 Dec 24, 02:00 PMJim Cramer on IDEXX Laboratories (IDXX): Is This Pet Stock Poised for a Comeback?
Fri 20 Dec 24, 09:02 PMWhat Does IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Indicate?
Fri 13 Dec 24, 11:00 AMA Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback
Tue 05 Nov 24, 12:00 AMIDEXX Laboratories, Inc. (IDXX): A Bull Case Theory
Thu 17 Oct 24, 03:43 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 859.97M | 902.65M | 661.99M | 522.22M | 457.74M |
| Minority interest | 0.00000M | 0.00100M | 0.35M | 0.07M | 0.02M |
| Net income | 679.09M | 744.85M | 581.78M | 427.72M | 377.03M |
| Selling general administrative | 326.25M | 309.66M | 300.83M | 261.32M | 244.94M |
| Selling and marketing expenses | 524.50M | 486.74M | 434.44M | 418.19M | 387.41M |
| Gross profit | 2004.34M | 1889.43M | 1571.04M | 1365.55M | 1241.54M |
| Reconciled depreciation | 111.90M | 104.60M | 96.00M | 88.01M | 83.18M |
| Ebit | 786.87M | 827.43M | 598.53M | 464.83M | 408.16M |
| Ebitda | 898.76M | 932.03M | 694.52M | 552.85M | 491.33M |
| Depreciation and amortization | 111.90M | 104.60M | 96.00M | 88.01M | 83.18M |
| Non operating income net other | 1.06M | 0.43M | 0.59M | 0.43M | 1.15M |
| Operating income | 898.76M | 932.03M | 694.52M | 552.85M | 491.33M |
| Other operating expenses | 2468.56M | 2283.33M | 2012.13M | 1854.06M | 1721.91M |
| Interest expense | 38.79M | 29.37M | 32.54M | 30.63M | 33.59M |
| Tax provision | 180.88M | 157.81M | 79.85M | 94.43M | 80.69M |
| Interest income | 1.06M | 0.43M | 0.59M | 0.43M | 1.15M |
| Net interest income | -38.79300M | -29.37400M | -32.53900M | -30.62800M | -33.59300M |
| Extraordinary items | - | - | - | - | -2.10000M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 180.88M | 157.81M | 79.85M | 94.43M | 80.69M |
| Total revenue | 3367.32M | 3215.36M | 2706.66M | 2406.91M | 2213.24M |
| Total operating expenses | 1105.57M | 957.40M | 876.52M | 812.70M | 750.21M |
| Cost of revenue | 1362.99M | 1325.93M | 1135.62M | 1041.36M | 971.70M |
| Total other income expense net | -38.79300M | -29.37400M | -32.53900M | -30.62800M | -33.59300M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 679.09M | 744.84M | 582.13M | 427.79M | 377.05M |
| Net income applicable to common shares | 679.09M | 744.85M | 581.78M | 427.72M | 377.03M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 3259.93M | 2746.76M | 2437.20M | 2294.56M | 1832.47M |
| Intangible assets | 84.50M | 97.67M | 99.03M | 52.54M | 58.47M |
| Earning assets | - | - | - | - | - |
| Other current assets | 203.59M | 220.49M | 173.82M | 137.51M | 124.98M |
| Total liab | 1775.39M | 2138.03M | 1747.21M | 1661.77M | 1654.65M |
| Total stockholder equity | 1484.53M | 608.74M | 689.99M | 632.09M | 177.47M |
| Deferred long term liab | - | 8.15M | 8.94M | 11.71M | 33.02M |
| Other current liab | 478.71M | 433.66M | 458.91M | 415.65M | 322.94M |
| Common stock | 10.75M | 10.72M | 10.69M | 10.65M | 10.57M |
| Capital stock | 10.75M | 10.72M | 10.69M | 10.65M | 10.57M |
| Retained earnings | 4444.57M | 3599.53M | 2920.44M | 2175.59M | 1595.65M |
| Other liab | - | 106.59M | 208.43M | 220.51M | 162.83M |
| Good will | 365.96M | 361.80M | 359.35M | 243.35M | 239.72M |
| Other assets | - | 387.48M | 893.88M | 676.66M | 240.19M |
| Cash | 453.93M | 112.55M | 144.45M | 383.93M | 90.33M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 951.55M | 1235.80M | 763.58M | 582.76M | 725.34M |
| Current deferred revenue | 37.20M | 37.94M | 40.03M | 42.57M | 41.46M |
| Net debt | 493.95M | 1235.82M | 779.25M | 524.55M | 897.35M |
| Short term debt | 325.00M | 653.98M | 148.50M | 49.99M | 288.76M |
| Short long term debt | 325.00M | 653.98M | 148.50M | 49.99M | 288.76M |
| Short long term debt total | 947.88M | 1348.37M | 923.70M | 908.48M | 987.67M |
| Other stockholder equity | -2899.58600M | -2923.71500M | -2187.65200M | -1500.53800M | -1382.56400M |
| Property plant equipment | - | 649.47M | 587.67M | 555.17M | 533.85M |
| Total current assets | 1495.25M | 1101.48M | 955.65M | 1062.74M | 679.64M |
| Long term investments | 56.19M | 55.50M | 13.35M | 12.06M | 13.66M |
| Net tangible assets | - | 149.27M | 689.99M | 336.20M | -120.71900M |
| Short term investments | - | - | - | - | - |
| Net receivables | 457.44M | 400.62M | 368.35M | 331.43M | 269.31M |
| Long term debt | 622.88M | 694.39M | 775.21M | 858.49M | 698.91M |
| Inventory | 380.28M | 367.82M | 269.03M | 209.87M | 195.02M |
| Accounts payable | 110.64M | 110.22M | 116.14M | 74.56M | 72.17M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | 0.71M | 0.35M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -71.20600M | -77.79600M | -53.48400M | -53.61500M | -46.18200M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 10.72M | 10.69M | 10.65M | 10.57M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 3599.53M | 2920.44M | 2175.59M | 1595.65M |
| Treasury stock | - | - | -3570.69100M | -2799.89000M | -2600.54300M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 448.48M | 425.63M | 397.37M | 337.15M | 299.04M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1764.67M | 1645.29M | 1481.55M | 1231.82M | 1152.84M |
| Capital lease obligations | 119.47M | 121.66M | 107.31M | 94.77M | 82.75M |
| Long term debt total | - | 694.39M | 775.21M | 858.49M | 698.91M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -195.35000M | -292.96700M | -109.37600M | -205.52800M | 284.04M |
| Change to liabilities | 3.47M | 11.23M | 0.98M | 1.96M | -0.16600M |
| Total cashflows from investing activities | -195.35000M | -292.96700M | -109.37600M | -205.52800M | 138.60M |
| Net borrowings | 430.06M | 23.50M | -94.65000M | -10.42900M | -256.04000M |
| Total cash from financing activities | -370.93600M | -697.41400M | -248.41600M | -286.40900M | -597.79900M |
| Change to operating activities | -102.84900M | -137.52300M | -31.76100M | -34.78800M | -39.73100M |
| Net income | 679.09M | 744.84M | 582.13M | 427.79M | 377.05M |
| Change in cash | -31.90800M | -239.47400M | 293.60M | -33.46800M | -63.88100M |
| Begin period cash flow | 144.45M | 383.93M | 90.33M | 123.79M | 187.68M |
| End period cash flow | 112.55M | 144.45M | 383.93M | 90.33M | 123.79M |
| Total cash from operating activities | 542.98M | 755.55M | 648.06M | 459.16M | 400.08M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 111.90M | 104.60M | 96.00M | 88.01M | 83.18M |
| Other cashflows from investing activities | -46.51200M | -173.41800M | -2.41800M | -50.55900M | -29.68500M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -121.73100M | -52.91900M | -18.88500M | -37.30600M | -25.62300M |
| Change to account receivables | -41.39800M | -33.14100M | -60.72200M | -22.47200M | -18.40100M |
| Sale purchase of stock | -830.31700M | -762.33900M | -203.41800M | -309.71100M | -378.69400M |
| Other cashflows from financing activities | 498.63M | 114.92M | 244.63M | 133.58M | 36.94M |
| Change to netincome | 25.52M | 148.22M | 1.70M | 48.32M | 31.50M |
| Capital expenditures | 148.84M | 119.55M | 107.63M | 155.22M | 122.94M |
| Change receivables | -41.39800M | -33.14100M | -60.72200M | -22.47200M | -18.40100M |
| Cash flows other operating | -113.86800M | -62.69600M | 46.87M | -47.14800M | -47.45000M |
| Exchange rate changes | - | - | - | - | -4.76800M |
| Cash and cash equivalents changes | -23.30200M | -234.83500M | 290.27M | -32.77900M | -63.88100M |
| Change in working capital | -273.53000M | -137.52300M | -31.76100M | -104.96900M | -91.64000M |
| Stock based compensation | 49.77M | 37.76M | 30.95M | 39.28M | 25.16M |
| Other non cash items | 10.82M | 9.25M | 8.83M | 2.88M | 5.13M |
| Free cash flow | 394.15M | 636.00M | 540.44M | 303.93M | 277.15M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IDXX IDEXX Laboratories Inc |
-9.36 2.18% | 419.26 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
| TMO Thermo Fisher Scientific Inc |
-2.06 0.37% | 559.65 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-3.54 1.46% | 238.36 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| IQV IQVIA Holdings Inc |
-0.3 0.15% | 197.36 | 37.82 | 19.68 | 2.76 | 7.20 | 3.61 | 17.03 |
| A Agilent Technologies Inc |
2.64 1.82% | 147.36 | 31.97 | 25.84 | 6.23 | 6.96 | 6.62 | 23.01 |
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
One IDEXX Drive, Westbrook, ME, United States, 04092
| Name | Title | Year Born |
|---|---|---|
| Mr. Jonathan J. Mazelsky | Pres, CEO & Director | 1961 |
| Mr. Brian P. McKeon | CFO, Exec. VP & Treasurer | 1962 |
| Mr. James F. Polewaczyk | Exec. VP & Chief Commercial Officer | 1964 |
| Mr. Michael J. Lane | Exec. VP and GM of Reference Laboratories & Information Technology | 1968 |
| Dr. Nimrata Khatra Hunt P.E., Ph.D. | Exec. VP and GM - Point of Care Diagnostics & Worldwide Operations | 1968 |
| Mr. John Hart | Sr. VP of Worldwide Operations | NA |
| Mr. Jeffery D. Chadbourne | Sr. Director of Accounting & Financial Reporting | 1976 |
| Dr. Martin Smith Ph.D. | Exec. VP & CTO | 1968 |
| Mr. Ken Grady | Sr. VP & Chief Information Officer | NA |
| Ms. Sharon E. Underberg | Exec. VP, Gen. Counsel, & Corp. Sec. | 1961 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...